The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients

¹Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands;
²Department of Medical Oncology, Ziekenhuisgroep Twente, Almelo, The Netherlands;
³Department of Nuclear Medicine, Catharina Hospital, Eindhoven, The Netherlands;
⁴Department of Radiology and Nuclear Medicine, Ziekenhuisgroep Twente, Almelo, Netherlands;
⁵Department of Nuclear Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands;
⁶Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, The Netherlands;
⁷Department of Biomedical Sciences, Humanitas University, Milan, Italy;
⁸Department of Nuclear Medicine, Humanitas Clinical and Research Center, Milan, Italy;
⁹Department of Nuclear Medicine, Reinier de Graaf Gasthuis, Delft, The Netherlands;
¹⁰Department of Medical Oncology, Reinier de G raaf Gasthuis and Reinier Haga Prostate Cancer Center, Delft, The Netherlands;
¹¹Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands;
¹²Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands;
¹³Department of Nuclear Medicine, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands; and
¹⁴Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands

For correspondence or reprints, contact Maarten J. van der Doelen (maarten.vanderdoelen{at}radboudumc.nl).

Statistics from Altmetric.com